1-9 of 9
John C. Panetta
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and FLT3-Internal Tandem Duplication

Hiroto Inaba, Jolieke G. van Oosterwijk, John C. Panetta, Lie Li, Daelynn R. Buelow, James S. Blachly, Sheila Shurtleff, Ching-Hon Pui, Raul C. Ribeiro, Jeffrey E. Rubnitz, Stanley Pounds, Sharyn D. Baker
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (12): 2536–2546.
https://doi.org/10.1158/1078-0432.CCR-21-4450
Published: 13 June 2022
View article titled, Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <em>FLT3</em>-Internal Tandem Duplication
Open the PDF for Preclinical and Pilot Study of Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib, with Sorafenib in Acute Myeloid Leukemia and <em>FLT3</em>-Internal Tandem Duplication in another window
Includes: Supplementary data
Journal Articles

Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies

Hiroto Inaba, John C. Panetta, Stanley B. Pounds, Lei Wang, Lie Li, Fariba Navid, Sara M. Federico, Eric D. Eisenmann, Aksana Vasilyeva, Yong-Dong Wang, Sheila Shurtleff, Ching-Hon Pui, Tanja A. Gruber, Raul C. Ribeiro, Jeffrey E. Rubnitz, Sharyn D. Baker
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (24): 7320–7330.
https://doi.org/10.1158/1078-0432.CCR-19-0470
Published: 13 December 2019
View article titled, Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies
Open the PDF for Sorafenib Population Pharmacokinetics and Skin Toxicities in Children and Adolescents with Refractory/Relapsed Leukemia or Solid Tumor Malignancies in another window
Includes: Supplementary data
Journal Articles

Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL+ B-Lineage Acute Lymphoblastic Leukemia

Amit Budhraja, Meghan E. Turnis, Michelle L. Churchman, Anisha Kothari, Xue Yang, Haiyan Xu, Ewa Kaminska, John C. Panetta, David Finkelstein, Charles G. Mullighan, Joseph T. Opferman
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2017) 23 (24): 7558–7568.
https://doi.org/10.1158/1078-0432.CCR-17-1231
Published: 14 December 2017
View article titled, Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL<sup>+</sup> B-Lineage Acute Lymphoblastic Leukemia
Open the PDF for Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL<sup>+</sup> B-Lineage Acute Lymphoblastic Leukemia in another window
Includes: Supplementary data
Journal Articles

Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Alberto Broniscer, Sharyn D. Baker, Cynthia Wetmore, Atmaram S. Pai Panandiker, Jie Huang, Andrew M. Davidoff, Arzu Onar-Thomas, John C. Panetta, Thomas K. Chin, Thomas E. Merchant, Justin N. Baker, Sue C. Kaste, Amar Gajjar, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (11): 3050–3058.
https://doi.org/10.1158/1078-0432.CCR-13-0306
Published: 30 May 2013
View article titled, Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Open the PDF for Phase I Trial, Pharmacokinetics, and Pharmacodynamics of Vandetanib and Dasatinib in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma in another window
Includes: Supplementary data
Journal Articles

Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors

Fariba Navid, Sharyn D. Baker, M. Beth McCarville, Clinton F. Stewart, Catherine A. Billups, Jianrong Wu, Andrew M. Davidoff, Sheri L. Spunt, Wayne L. Furman, Lisa M. McGregor, Shuiying Hu, John C. Panetta, David Turner, Demba Fofana, Wilburn E. Reddick, Wing Leung, Victor M. Santana
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 236–246.
https://doi.org/10.1158/1078-0432.CCR-12-1897
Published: 02 January 2013
View article titled, Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors
Open the PDF for Phase I and Clinical Pharmacology Study of Bevacizumab, Sorafenib, and Low-Dose Cyclophosphamide in Children and Young Adults with Refractory/Recurrent Solid Tumors in another window
Journal Articles

Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma

Trevor McKibbin, John C. Panetta, Maryam Fouladi, Amar Gajjar, Feng Bai, M. Fatih Okcu, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (3): 1049–1057.
https://doi.org/10.1158/1078-0432.CCR-09-1997
Published: 01 February 2010
View article titled, Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma
Open the PDF for Clinical Pharmacokinetics of Amifostine and WR1065 in Pediatric Patients with Medulloblastoma in another window
Includes: Supplementary data
Journal Articles

Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma

John C. Panetta, Paula Schaiquevich, Victor M. Santana, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (1): 318–325.
https://doi.org/10.1158/1078-0432.CCR-07-1243
Published: 02 January 2008
View article titled, Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma
Open the PDF for Using Pharmacokinetic and Pharmacodynamic Modeling and Simulation to Evaluate Importance of Schedule in Topotecan Therapy for Pediatric Neuroblastoma in another window
Journal Articles

Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients

Paula Schaiquevich, John C. Panetta, Lisa C. Iacono, Burgess B. Freeman, III, Victor M. Santana, Amar Gajjar, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (22): 6703–6711.
https://doi.org/10.1158/1078-0432.CCR-07-1376
Published: 15 November 2007
View article titled, Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients
Open the PDF for Population Pharmacokinetic Analysis of Topotecan in Pediatric Cancer Patients in another window
Includes: Supplementary data
Journal Articles

Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420

Alberto Broniscer, John C. Panetta, Melinda O'Shaughnessy, Charles Fraga, Feng Bai, Matthew J. Krasin, Amar Gajjar, Clinton F. Stewart
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (5): 1511–1515.
https://doi.org/10.1158/1078-0432.CCR-06-2372
Published: 01 March 2007
View article titled, Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420
Open the PDF for Plasma and Cerebrospinal Fluid Pharmacokinetics of Erlotinib and Its Active Metabolite OSI-420 in another window